Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 57.05

-0.6%

Dec 9 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (5358)	1/7/2002 10:33:57 PM
From: Jibacoa	Read Replies (1) of 52153

Peter: Do you have any idea how much the possible liability from troglitazone may affect PFE. ? I understand that in a recent trial in Texas the jury's verdict was for the defendant, but on that case the cause of death was renal failure and the woman was already missing one kidney by the time she was started on Rezulin. But there are several hundred cases already filed and some in which there has been substantial liver damage. In one case the plaintiff is waiting for a possible liver transplant. I am glad that I never prescribed the drug in spite of the strong marketing pressure from the Parke-Davis detail people.<g> Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next